Friday, May 18, 2018
Dipharma Francis S.r.l., a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.
Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all of the issued and outstanding shares of Kalexsyn through its American subsidiary Dipharma, Inc.
Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and provides chemistry services that support the drug discovery and development activities of their customers.